FindTrial
Sign In

Sotrovimab Expanded Access Treatment Protocol (COVID-19)

Sotrovimab Expanded Access Treatment Protocol

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT05235347
Enrollment
Unknown
Registered
2022-02-11
Start date
Unknown
Completion date
Unknown
Last updated
2022-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Keywords

SARS-CoV-2, coronavirus, coronavirus disease 2019, COVID-19

Brief summary

An expanded access program for sotrovimab administered intravenously to participants with COVID-19 illness who meet current authorized/approved criteria for use of sotrovimab.

Interventions

BIOLOGICALSotrovimab

500mg IV

Sponsors

Vir Biotechnology, Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
12 Years to No maximum

Inclusion criteria

* In the opinion of the investigator, meets the current Emergency Use Authorization (EUA) eligibility criteria for sotrovimab OR * patients currently hospitalized for a non-COVID-19 illness who acquire COVID-19 (nosocomial infection) and otherwise meets all the current EUA eligibility criteria

Exclusion criteria

* Hospitalized due to COVID-19 (excludes nosocomial infection) * Require oxygen therapy due to COVID-19, OR who require an increase in baseline oxygen flow rate due to COVID-19

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026